300267 Stock Overview
Manufactures and sells APIs, finished drug products, and pharmaceutical excipients in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Hunan Er-Kang Pharmaceutical Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥3.21 |
| 52 Week High | CN¥3.88 |
| 52 Week Low | CN¥2.03 |
| Beta | 0.36 |
| 1 Month Change | 4.22% |
| 3 Month Change | 47.25% |
| 1 Year Change | -0.31% |
| 3 Year Change | -24.82% |
| 5 Year Change | -39.55% |
| Change since IPO | 32.20% |
Recent News & Updates
Subdued Growth No Barrier To Hunan Er-Kang Pharmaceutical Co., Ltd (SZSE:300267) With Shares Advancing 27%
Sep 30
Hunan Er-Kang Pharmaceutical (SZSE:300267) Has Debt But No Earnings; Should You Worry?
Sep 26Recent updates
Subdued Growth No Barrier To Hunan Er-Kang Pharmaceutical Co., Ltd (SZSE:300267) With Shares Advancing 27%
Sep 30Hunan Er-Kang Pharmaceutical (SZSE:300267) Has Debt But No Earnings; Should You Worry?
Sep 26What Hunan Er-Kang Pharmaceutical Co., Ltd's (SZSE:300267) 28% Share Price Gain Is Not Telling You
Aug 08Health Check: How Prudently Does Hunan Er-Kang Pharmaceutical (SZSE:300267) Use Debt?
Jun 03Pinning Down Hunan Er-Kang Pharmaceutical Co., Ltd's (SZSE:300267) P/S Is Difficult Right Now
Mar 27Shareholder Returns
| 300267 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -10.3% | -4.3% | -3.5% |
| 1Y | -0.3% | -3.4% | 10.9% |
Return vs Industry: 300267 exceeded the CN Pharmaceuticals industry which returned -3.1% over the past year.
Return vs Market: 300267 underperformed the CN Market which returned 11.8% over the past year.
Price Volatility
| 300267 volatility | |
|---|---|
| 300267 Average Weekly Movement | 9.9% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 300267 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300267's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 1,497 | Qingrong Sun | www.hnerkang.com |
Hunan Er-Kang Pharmaceutical Co., Ltd manufactures and sells APIs, finished drug products, and pharmaceutical excipients in China and internationally. Its APIs include glycerin, dilute hydrochloric acid, sulbenicillin sodium, dihydroxypropyl theophylline, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. The company’s finished drugs primarily comprise sulbenicillin sodium for injection and compound liquorice tablets.
Hunan Er-Kang Pharmaceutical Co., Ltd Fundamentals Summary
| 300267 fundamental statistics | |
|---|---|
| Market cap | CN¥6.62b |
| Earnings (TTM) | -CN¥260.86m |
| Revenue (TTM) | CN¥1.19b |
5.6x
P/S Ratio-25.4x
P/E RatioIs 300267 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300267 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.19b |
| Cost of Revenue | CN¥999.83m |
| Gross Profit | CN¥192.21m |
| Other Expenses | CN¥453.07m |
| Earnings | -CN¥260.86m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.13 |
| Gross Margin | 16.12% |
| Net Profit Margin | -21.88% |
| Debt/Equity Ratio | 8.5% |
How did 300267 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 06:24 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hunan Er-Kang Pharmaceutical Co., Ltd is covered by 10 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yalei Yan | Bohai Securities Co., Ltd. |
| Shuchang Liu | Changjiang Securities Co. LTD. |
| Jing Qiang | China International Capital Corporation Limited |